A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML
TerminatedNCT05933070
Inmune Bio, Inc.Acute Myeloid Leukemia, AML, Cancer +2
Start: 2020-06-15End: 2024-04-26Updated: 2026-03-30
Study of INKmune in Patients With mCRPC (CaRe Prostate)
CompletedNCT06056791
Inmune Bio, Inc.Cancer, mCRPC, Metastatic Castration-resistant Prostate Cancer
Start: 2023-11-30End: 2025-09-10Updated: 2026-02-27